The Southwest Oncology Group is an adult multi-disease, multi-modality clinical research organization with 33 Member Institutions, 23 Community Clinical Oncology Program (CCOP) institutions, including 5 Minority- Based CCOPs, 27 Urologic Cancer Outreach Program (UCOP) members, 22 High Priority program members and a network of 1,441 Cooperative Group Outreach Program (CGOP) investigators at 272 affiliate hospitals, and 15 institutions participating in the CTEP Minority program. Special emphasis areas for the Group with respect to the inclusion of women and minorities have come under the responsibility of the new Committee on Women and Special Populations. This group will focus on detailed analyses of women in the various disease categories. There have been gender differences identified in melanoma and lung cancer trials. The special populations include a commitment to optimize the enrollment of minorities in Group trials. Analyses of race and ethnicity impacts on the outcome of patients in our clinical trials are in progress. Additional special populations include the elderly patient advocates, and survivors of cancer. The Committee on Women and Special Populations portion of this application details the heavy current and future involvement of patient advocates in the committee activities of the Group. The Group will involve cancer survivors in our clinical trial committee structure. The Chairman of the Group has created an ethics training program which is delivered between 2-3 times to separate audiences, at every Group Meeting in order to help members understand the moral and ethical principles of the conduct of clinical trials. Tied to this, is the fully implemented Conflict of Interest Policy which identifies potential conflicts from all investigators, who then agree to recuse themselves from decision making related to their identified potential conflict(s) of interest. We have an Affirmation of Integrity statement on file for all members of the Group that come in contact with clinical trial data. The Group application includes correlative biologic studies from banked tumor specimens of homogeneously treated patients in breast, gastrointestinal, head and neck, leukemia, lymphoma, and multiple myeloma cancers. There are two new initiatives involved in this application. A proposal in lung cancer biology proposes a 2-year study of the molecular composition of lung cancer specimens obtained from patients on completed Group clinical trials. The second new initiative deals with a 5-year plan for upgrading Informatics at the Statistical Center and at Group institutions to become ready for all electronic data and information transfer into the future.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA032102-20S1
Application #
6349686
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1981-07-16
Project End
2002-12-31
Budget Start
2000-01-01
Budget End
2000-12-31
Support Year
20
Fiscal Year
2000
Total Cost
$800,000
Indirect Cost
Name
Cancer Therapy and Research Center
Department
Type
DUNS #
010550366
City
San Antonio
State
TX
Country
United States
Zip Code
78229
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594
Ni, Haiwen; Shirazi, Fazal; Baladandayuthapani, Veerabhadran et al. (2018) Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res 24:6408-6420
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Francis, Prudence A; Pagani, Olivia; Fleming, Gini F et al. (2018) Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med 379:122-137
Hao, Suyang; Lin, Pei; Medeiros, L Jeffrey et al. (2017) Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion. Mod Pathol 30:1378-1386
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Saha, Poornima; Regan, Meredith M; Pagani, Olivia et al. (2017) Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol 35:3113-3122
Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465
Stock, W; Diouf, B; Crews, K R et al. (2017) An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia. Clin Pharmacol Ther 101:391-395

Showing the most recent 10 out of 742 publications